quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:15:02·46d
SECFiling
enGene Therapeutics Inc. logo

enGene Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement

ENGN· enGene Therapeutics Inc.
Health Care
Original source

Companies

  • ENGN
    enGene Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Apr 13UpdateWBB Securities$21.50
  • Jan 30UpdateJefferies$28.00
  • Nov 11UpdateRaymond James$27.00
  • Feb 18UpdatePiper Sandler$26.00
  • Feb 14UpdateUBS$7.00
  • Dec 23UpdateH.C. Wainwright$25.00

Related

  • ANALYST10d
    WBB Securities initiated coverage on enGene Therapeutics with a new price target
  • SEC14d
    enGene Therapeutics Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
  • PR35d
    Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care
  • SEC45d
    SEC Form S-8 filed by enGene Holdings Inc.
  • SEC46d
    SEC Form 424B5 filed by enGene Holdings Inc.
  • SEC46d
    SEC Form 10-Q filed by enGene Holdings Inc.
  • SEC46d
    enGene Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
  • PR46d
    enGene Reports First Quarter 2026 Financial Results and Provides Business Update
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022